Cafcit and Terbinex
Determining the interaction of Cafcit and Terbinex and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Terbinafine may decrease the clearance of intravenously administered caffeine by 19% to 21%. The mechanism of the interaction has not been delineated. Although this interaction is unlikely to be of clinical significance, it may be appropriate to monitor the patient for increased caffeine effects.
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cafcit-Terbutaline
- Cafcit-Terbutaline Injection
- Cafcit-Terbutaline Subcutaneous
- Cafcit-Terbutaline Sulfate
- Cafcit-Terbutaline Tablets
- Cafcit-Teriflunomide
- Terbinex-Cafcit (Caffeine Citrate Injection Solution)
- Terbinex-Cafcit (Caffeine Citrate Oral Solution)
- Terbinex-Cafcit Intravenous
- Terbinex-Cafcit Oral
- Terbinex-Cafergot (Ergotamine and Caffeine Suppositories)
- Terbinex-Cafergot (Ergotamine and Caffeine Tablets)